^
Association details:
| Biomarker: | AGO2 overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | VRD (bortezomib + dexamethasone injection + lenalidomide) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Published date:
12/07/2020
Excerpt:
High levels of PSMD1, PSMD4, and PSMD10-gankyrin were associated with adverse prognosis, leading to shorter TTP (median, 40, 48, and 52 months, respectively) compared with patients with lower levels of those proteins who had not reached the median TTP....Conversely, high level of Ikaros, AGO2, and Aiolos were significantly associated with shorter TTP.
DOI:
10.1182/bloodadvances.2020002711
Trial ID:
